Finnish CDMO Biovian earmarks €50M to expand advanced therapy production site

Preview

来源: FiercePharma

Biovian expects its site expansion in Turku, Finland, to be complete by 2025.

Biovian, a Finland-based CDMO, earmarked 50 million euros ($55 million) to expand its advanced therapy manufacturing operations in Turku, Finland.

The project will feature a new 69,000-square-foot facility to support the development, manufacturing, and testing of advanced treatments such as adenoviral and AAV (adeno-associated viral) therapies, the company said in a July 26 press release.

The site will also house cleanroom areas for bulk drug substances, plus have the capability to produce final drug products. Biovian expects the project to be complete by December 2024 and fully operational by 2025.

Biovian's expansion is expected to create 100 new jobs when finished, the company says. The CDMO currently employs about 200.

Headquartered in Turku, Biovian isn't the only biopharma player in the Finnish city. In fact, Turku is best known in the industry as being the “contraceptive” capital of the world thanks to Bayer's presence there.

Back in June 2021, Bayer said it would spend $303 million to build a new production plant in Turku that the German pharma giant said would be "one of the most modern" factories in the world featuring automation and robotics. Part of the company's investment in Turku also included upgrades to its existing facility there.

The Bayer expansion is expected to be finished by 2025.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。